
Introductory Session

8:00 – 8:15 Welcome and Introduction
Kelly Caudle, PharmD, PhD (St. Jude Children's Research Hospital)

Session I: Strategies for Implementing Pharmacogenetics

8:15 – 8:50 Outcomes with *CYP2C19* genotyping for clopidogrel response: an update from the IGNITE Network
Larisa Cavallari, PharmD (University of Florida)

8:50 – 9:25 Economic considerations for implementation
Josh Peterson, MD, MPH (Vanderbilt University Medical Center)

9:25 – 10:00 Using EHR for implementation/PharmCAT
Marylyn Ritchie, PhD (Geisinger Health System)

10:00 – 10:35 CPIC tables for EHR implementation
Mary Relling, PharmD (St. Jude Children's Research Hospital)

10:35 – 10:50 BREAK

Session II: Tougher Cases for Implementation

10:50 – 11:25 Implementation of warfarin pharmacogenetics by race groups
Stuart Scott, PhD (Icahn School of Medicine at Mount Sinai)

11:25 – 12:00 *CYP2D6* genotype and the use of tamoxifen in breast cancer
Matthew Goetz, MD (Mayo Clinic)

12:00 – 12:30 Panel Discussion
Sessions I and II Speakers

12:30 – 1:00 LUNCH

Session III: Global Perspectives for Pharmacogenetics Implementation

1:00 – 1:35 Global implementation of genomic medicine
Howard McLeod, PharmD (Moffitt Cancer Center)

1:35 – 2:10 Pharmacogenetics implementation: European perspectives
Munir Pirmohamed, PhD (University of Liverpool)

2:10 – 2:40 Pharmacogenetics implementation: Asian perspectives
Ming Ta Michael Lee, PhD (Geisinger Health System)

2:40 – 2:55 BREAK

2:55 – 3:25 Pharmacogenetics implementation: African perspectives
Collen Masimirembwa, PhD (African Institute of Biomedical Science and Technology)

3:25 – 3:50 Panel Discussion
Session III Speakers

3:50 – 4:00 WRAP UP